WallStreetZenWallStreetZen

NASDAQ: PAHC
Phibro Animal Health Corp Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for PAHC

Based on 2 analysts offering 12 month price targets for Phibro Animal Health Corp

Min Forecast
$22.00+27.24%
Avg Forecast
$23.50+35.92%
Max Forecast
$25.00+44.59%

Should I buy or sell PAHC stock?

Based on 2 analysts offering ratings for Phibro Animal Health Corp.

Sell
Strong Buy
0 analysts 0%
Buy
0 analysts 0%
Hold
1 analysts 50%
Sell
0 analysts 0%
Strong Sell
1 analysts 50%
Although PAHC's forecast from analysts indicates a "Sell", our proven Zen Rating quant model rates PAHC as a "Buy". Stocks with a Zen Rating of Buy have had an average return of +19.88% per year. Learn More

Be the first to know when Wall Street analysts revise their PAHC stock forecasts and price targets.

PAHC stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-02-10
lockedlocked$00.00+00.00%2024-12-17

1 of 1

Forecast return on equity

Is PAHC forecast to generate an efficient return?

Company
37.8%
Industry
38.52%
Market
61.97%
PAHC's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is PAHC forecast to generate an efficient return on assets?

Company
7.26%
Industry
13.77%
PAHC is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

PAHC earnings per share forecast

What is PAHC's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$1.94+303.13%
Avg 2 year Forecast
$2.11+338.54%
Avg 3 year Forecast
$2.30+379.85%
PAHC's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

PAHC revenue forecast

What is PAHC's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$1.3B+15.45%
Avg 2 year Forecast
$1.4B+24.9%
Avg 3 year Forecast
$1.4B+29.51%
PAHC's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

PAHC earnings growth forecast

How is PAHC forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?

Company
109.86%
Industry
31.05%
Market
23.64%
PAHC's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
PAHC's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
PAHC's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

PAHC revenue growth forecast

How is PAHC forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?

Company
11.03%
Industry
4.41%
Market
10.7%
PAHC's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
PAHC's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

PAHC vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
PAHC$17.29$23.50+35.92%Sell
EOLS$10.79$23.75+120.11%Strong Buy
CRON$1.77N/AN/A
AVDL$8.03$18.17+126.24%Strong Buy
COLL$27.01$44.00+62.90%Buy
View Top Pharmaceutical Stocks

Phibro Animal Health Stock Forecast FAQ

Is Phibro Animal Health Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: PAHC) stock is to Sell PAHC stock.

Out of 2 analysts, 0 (0%) are recommending PAHC as a Strong Buy, 0 (0%) are recommending PAHC as a Buy, 1 (50%) are recommending PAHC as a Hold, 0 (0%) are recommending PAHC as a Sell, and 1 (50%) are recommending PAHC as a Strong Sell.

If you're new to stock investing, here's how to buy Phibro Animal Health stock.

What is PAHC's earnings growth forecast for 2025-2027?

(NASDAQ: PAHC) Phibro Animal Health's forecast annual earnings growth rate of 109.86% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 31.05%, and it is also forecast to beat the US market's average forecast earnings growth rate of 23.64%.

Phibro Animal Health's earnings in 2025 is $19,317,000.On average, 4 Wall Street analysts forecast PAHC's earnings for 2025 to be $78,374,481, with the lowest PAHC earnings forecast at $76,956,855, and the highest PAHC earnings forecast at $80,602,180. On average, 4 Wall Street analysts forecast PAHC's earnings for 2026 to be $85,260,095, with the lowest PAHC earnings forecast at $79,792,108, and the highest PAHC earnings forecast at $91,943,190.

In 2027, PAHC is forecast to generate $93,291,960 in earnings, with the lowest earnings forecast at $87,082,757 and the highest earnings forecast at $102,474,128.

What is PAHC's revenue growth forecast for 2025-2027?

(NASDAQ: PAHC) Phibro Animal Health's forecast annual revenue growth rate of 11.03% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.41%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.7%.

Phibro Animal Health's revenue in 2025 is $1,106,080,000.On average, 3 Wall Street analysts forecast PAHC's revenue for 2025 to be $51,720,191,156, with the lowest PAHC revenue forecast at $51,047,304,717, and the highest PAHC revenue forecast at $52,312,434,912. On average, 3 Wall Street analysts forecast PAHC's revenue for 2026 to be $55,957,516,611, with the lowest PAHC revenue forecast at $53,384,727,431, and the highest PAHC revenue forecast at $59,953,845,598.

In 2027, PAHC is forecast to generate $58,019,636,301 in revenue, with the lowest revenue forecast at $54,483,347,294 and the highest revenue forecast at $61,569,129,485.

What is PAHC's forecast return on assets (ROA) for 2025-2027?

(NASDAQ: PAHC) forecast ROA is 7.26%, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of 13.77%.

What is PAHC's Price Target?

According to 2 Wall Street analysts that have issued a 1 year PAHC price target, the average PAHC price target is $23.50, with the highest PAHC stock price forecast at $25.00 and the lowest PAHC stock price forecast at $22.00.

On average, Wall Street analysts predict that Phibro Animal Health's share price could reach $23.50 by Feb 10, 2026. The average Phibro Animal Health stock price prediction forecasts a potential upside of 35.92% from the current PAHC share price of $17.29.

What is PAHC's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: PAHC) Phibro Animal Health's current Earnings Per Share (EPS) is $0.48. On average, analysts forecast that PAHC's EPS will be $1.94 for 2025, with the lowest EPS forecast at $1.90, and the highest EPS forecast at $1.99. On average, analysts forecast that PAHC's EPS will be $2.11 for 2026, with the lowest EPS forecast at $1.97, and the highest EPS forecast at $2.27. In 2027, PAHC's EPS is forecast to hit $2.30 (min: $2.15, max: $2.53).

What is PAHC's forecast return on equity (ROE) for 2025-2027?

(NASDAQ: PAHC) forecast ROE is 37.8%, which is considered strong.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.